Stock·NYSE·Healthcare
Oscar Health, Inc. (OSCR)
- Market cap
- $9.37B
- P/E
- 23.54
- Dividend yield
- None
- Street target
- $34.00median of 11 analysts
- 52-week range
- $10.69 $35.01
OSCR stock forecast today
Where OSCR stands today, and what CleaRank Financial AI makes of it.
OSCR at a glance
Oscar Health, Inc. (OSCR): Buy, 73/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($23.60 and $31.71).
- Earnings OSCR beat estimates in 3 of the 7 reports in our data, and the stock rose the next day every time.
- Insiders Insiders sold $157.7M and bought $11.9M over the last 18 months.
- Valuation P/E of 23.5 against 31.9 for the Healthcare sector: a discount to peers (-26%).
Figures as of October 30, 2026.
CleaRank Financial AI
Oscar Health, Inc. (OSCR) carries a CleaRank rating of Buy and a model score of 73/100.
Trend does the most to lift that score: the price is 28.68% above its 200-day average, and the 50-day average is 34.37% above the 200-day. Momentum pulls hardest in the other direction, with the MACD line negative. The 50-day average is $31.71 and the 200-day is $23.60, and the stock gained 67.88% over the last twelve months.
Only on CleaRank
Figures we compute ourselves from OSCR's own price, earnings and insider-filing history. Tap one to see it in context.
OSCR stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price below its 50-day average ›
The price of $30.37 is 4.2% below the 50-day simple moving average of $31.71.Price above its 200-day average ›
The price is 28.7% above the 200-day simple moving average of $23.60.50-day average above the 200-day ›
The 50-day average ($31.71) is 34.4% above the 200-day average ($23.60), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 81% of its 52-week range, between $10.69 and $35.01.
OSCR share price
Pick a period: each tab shows how far OSCR has moved over it, to the last close.
Today's trading
Where OSCR sits inside today's range and its 52-week range.
OSCR fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/4P/E below the sector median ›
The trailing P/E of 23.54 is 26.2% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 0.61 is 82.0% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $550.7M on revenue of $15.3B, a net margin of 3.6%.Missed estimates in most recent reports ›
OSCR beat the EPS estimate in 3 of the 7 reports in our data.
Key statistics
The headline figures for OSCR.
As of October 30, 2026, OSCR trades at $30.37, with a market value of $9.37B and a P/E ratio of 23.54.
What the numbers say
CleaRank Financial AI's reading of OSCR's valuation, growth and risks.
Oscar Health, Inc. (OSCR) trades at a P/E of 23.54 against a Healthcare median of 31.9, which makes it a discount to peers, with the P/E 26.2% under that median. On sales, the P/S of 0.61 sits 82.1% below the sector median of 3.4. The company carries a market value of $9.4B, and its trailing earnings come to $1.29 per share.
Year on year, revenue expanded 70.40% in the latest quarter, running 62.3 percentage points ahead of the Healthcare sector median of 8.1%. A net margin of 3.60% and an operating margin of 7.96% describe the profit side of the business. Return on equity stands at 34.26%, above the sector median of 7.3%; this measures how much profit the company generates from shareholders' capital. Debt-to-equity is 0.23.
OSCR's most recent earnings report, dated August 6, 2026, showed EPS of $1.10, compared with the $0.38 that analysts had expected. That result beat the estimate by 189.47%. The shares climbed 5.12% in the following session.
Over the 7 reports in our data, OSCR topped the estimate 3 times, and the stock rose in the first session after each of those beats. The August 6, 2025 report stands out among the few before the latest: a miss of 5.95%, after which the stock rose 5.72%. Looking ahead, analysts expect EPS of $1.94 this fiscal year and $2.22 the year after (growth of 14.3%).
Day-to-day volatility is the first thing to plan around: OSCR has moved 2.71% on an average session with a beta of 2.47 against the S&P 500. Over the last 18 months, insider sales totalled $157.7M against $11.9M of purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
OSCR against the Healthcare sector
How OSCR compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: OSCR trades at a notable discount to sector peers (-26%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 20, 2025, OSCR has gained 84.4% against a gain of 37.3% for XLV.
Performance against XLV
OSCR and the Healthcare sector fund over the same days.
Revenue and earnings
How much OSCR sells, and how much of it becomes profit.
Revenue growth: Revenue grew 27.5% in FY2025 to $11.7B, from $9.2B a year earlier.
Profit margin: The net margin was -3.8% in FY2025, down from 0.3% the year before.
Loss-making: OSCR lost $443M in FY2025.
Earnings reality check
Did OSCR beat what analysts expected, and how did the stock react?
Earnings record: OSCR beat the analyst estimate in 3 of the 7 reports in our data.
Market reaction: The stock rose in the first session after every beat.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 6, 2026after close | $0.38 | $1.10 | +189.47% | +5.12% | +15.98% |
| May 6, 2026after close | $1.10 | $2.07 | +88.18% | +5.19% | +19.05% |
| Feb 10, 2026after close | -$0.92 | -$1.24 | -34.78% | +5.59% | +6.37% |
| Aug 6, 2025after close | -$0.84 | -$0.89 | -5.95% | +5.72% | +4.11% |
| May 7, 2025after close | $0.81 | $0.92 | +13.58% | +0.24% | -2.82% |
| Feb 4, 2025after close | -$0.58 | -$0.62 | -6.90% | +3.08% | -7.66% |
| Nov 7, 2024after close | -$0.18 | -$0.22 | -22.22% | -0.73% | +13.20% |
As of October 30, 2026, OSCR has beaten the analyst EPS estimate in 3 of the 7 reports in our data and rose in the first trading session after every one of those beats; its latest report, on August 6, 2026, came in 189.47% above the estimate and the stock moved +5.12% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
OSCR AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 41.5, in neutral territory.RSI below 50 ›
An RSI of 41.5 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line below zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank Financial AI analysis of OSCR
The score, the reasoning behind it, and what could move the price next.
Oscar Health, Inc. (OSCR) is caught between its two moving averages. At $30.37, the stock trades 28.68% above its 200-day average of $23.60 but 4.24% below its 50-day average of $31.71. Sitting at 81% of its 52-week range, the price is 13.25% under the 52-week high of $35.01. The 50-day average is 34.37% above the 200-day average, and that spread would shrink if the price keeps trading under the shorter average.
A recent pullback sits inside a stronger longer record: the price fell 1.52% over the past month, fell 2.72% over the past three months and rose 67.88% over the past year. On momentum, the 14-day RSI reads 41.5, in the neutral zone, with the MACD line negative.
Earnings beat ›
The August 6, 2026 report beat the EPS estimate by 189.47%, and the share price rose 5.12% in the first session after it.
Source: Earnings report, August 6, 2026
Rating reaffirmed ›
UBS kept its Neutral rating on October 12, 2026.
Source: Analyst action, UBS, October 12, 2026
- The two levels closest to the price are the 50-day SMA at $31.71, which sits above it, and the 200-day SMA at $23.60, which sits below.
- The 14-day RSI reads 41.5, in the neutral zone, with the MACD line negative; readings above 70 or below 30 mark stretched momentum.
- The share price climbed 5.12% in the first session after the August 6, 2026 report. Across the 7 reports in our data, OSCR has beaten estimates in 3.
OSCR's signals point in different directions. It sits above its 200-day average of $23.60 but under its 50-day average of $31.71. Should the price close above the 50-day, both readings would turn upward; a close below the 200-day would turn both downward. For now the price is wedged between the 200-day SMA ($23.60) below and the 50-day SMA ($31.71) above.
OSCR's 14-day RSI reads 41.5, which places the stock in the neutral zone between 40 and 60.
Technical indicators
Momentum and trend for OSCR, from its daily closes.
As of October 30, 2026, with OSCR at $30.37, its 14-day RSI is 41.5 (neutral territory), its 50-day simple moving average is $31.71 and its 200-day is $23.60.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What OSCR moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, OSCR's 1-year correlation of daily returns is +0.22 with S&P 500 (SPY), +0.19 with Nasdaq 100 (QQQ), +0.23 with Bitcoin (BTC) and +0.03 with gold (XAU).
OSCR price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
1/3Fewer than half of analysts rate it a buy ›
3 of 11 analysts rate it a buy or strong buy, 7 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $34.00 is 12.0% above the price.No more buy ratings than three months ago ›
3 of 11 rate it a buy now, against 3 of 11 three months ago.
OSCR Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 12, 2026 | UBS | Maintains | Neutral |
| Sep 18, 2026 | Raymond James | Maintains | Outperform |
| Sep 17, 2026 | B of A Securities | Maintains | Underperform |
| Sep 17, 2026 | Stephens & Co. | Reiterates | Equal-Weight |
| Sep 17, 2026 | Barclays | Maintains | Overweight |
| Sep 17, 2026 | Baird | Maintains | Neutral |
As of October 30, 2026, 11 Wall Street analysts cover OSCR: 3 rate it a buy or strong buy, 7 a hold and 1 a sell or strong sell. Their 12-month price targets range from $27.00 to $49.00. The median OSCR price target is $34.00, 12.0% above the price of $30.37.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
OSCR trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
OSCR trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from OSCR's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much OSCR tends to move, against the market and on its own.
OSCR price history and drawdowns
OSCR's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move of 2% or more ›
The price has moved 2.71% on an average day (30-day standard deviation of daily returns).Not yet recovered from its worst fall ›
The worst fall was 94.2%, from March 2021 to December 2022; the price is still 17.4% below that peak.Most 1-year holds ended higher ›
57% of 1-year holding periods in the last 6 years ended with a gain.Trailed the S&P 500 since the chart begins ›
$10,000 invested in March 2021 is now worth $8,727, against $21,386 in the S&P 500 (SPY).
OSCR Drawdowns & Recovery
As of October 30, 2026, OSCR's worst peak-to-trough fall over the period since March 2021 with dividends reinvested was -94.2% (March 2021 to December 2022); it is still 17.4% below that peak, and 57% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into OSCR in March 2021 is worth now, against the same amount in the S&P 500.
Against the market: OSCR trailed the S&P 500 over this period: $8,727.01 against $21,386.
A $10,000 investment in OSCR in March 2021 would be worth about $8,727 today with dividends reinvested, compared with about $21,386 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to OSCR, and which have not.
Strongest month, January: an average of +19.28%, up in 4 of 5 years.
Weakest month, December: an average of -12.46%, up in 1 of 5 years.
This month, October: has averaged -12.03%, up in 1 of 5 years. Past seasonality does not repeat on schedule.
Over the last 6 years, OSCR's strongest calendar month has been January (average +19.28%, up in 4 of 5 years) and its weakest December (average -12.46%, up in 1 of 5 years).
Average return for each calendar month over the last 6 years, from weekly closing prices with dividends included.
OSCR stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in OSCR, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 6 years of price history, projects that a $10,000 investment in OSCR today could grow to about $10,722 by 2030 in the base case, with a 90th-percentile outcome near $38,626 and a 10th-percentile outcome around $2,976. Projections are statistical simulations, not guarantees.
OSCR Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $32.56 for OSCR by 2030 in the base case, from $30.37 today (1.1x over 4 years). The 10th-percentile path ends near $9.04. These are outcomes of a Monte Carlo simulation run on OSCR's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $16.28 | $30.90 | $58.66 | |
| 2028 | $12.71 | $31.45 | $77.83 | |
| 2029 | $10.55 | $32.00 | $97.09 | |
| 2030 | $9.04 | $32.56 | $117 |
Method: a lognormal simulation of OSCR's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
OSCR insider trading
What the people running the company have bought and sold.
OSCR insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $11.9M on the open market and sold $157.7M.
As of October 30, 2026, OSCR insiders reported 36 open-market sales worth $157.7M and 1 open-market purchase worth $11.9M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 18, 2026 | Vanessa Ames Wittman
Director
|
Sell | 25.0K | $806.0K |
| Sep 3, 2026 | Mario T Schlosser
Director
|
Sell | 31.4K | $988.2K |
| Sep 3, 2026 | Richard Scott Blackley
Chief Financial Officer
|
Sell | 28.9K | $907.9K |
| Sep 3, 2026 | Janet Liang
Officer
|
Sell | 10.4K | $325.8K |
| Sep 3, 2026 | Adam Mcananey
Officer
|
Sell | 9.1K | $285.9K |
| Sep 3, 2026 | Victoria Baltrus
Officer
|
Sell | 958 | $30.1K |
| Aug 28, 2026 | Mario T Schlosser
Director
|
Sell | 750.0K | $22.8M |
| Aug 28, 2026 | Mario T Schlosser
Director
|
Grant | 750.0K | - |
| Aug 18, 2026 | Richard Scott Blackley
Chief Financial Officer
|
Sell | 18.8K | $595.1K |
| Jul 1, 2026 | Mario T Schlosser
Director
|
Sell | 47.5K | $1.5M |
| Jul 1, 2026 | Mario T Schlosser
Director
|
Grant | 47.5K | - |
| Jun 30, 2026 | Mark T Bertolini
Chief Executive Officer
|
Sell | 1.2M | $35.8M |
| Jun 26, 2026 | Mark T Bertolini
Chief Executive Officer
|
Sell | 1.2M | $34.9M |
| Jun 23, 2026 | Mario T Schlosser
Director
|
Sell | 1.0M | $30.2M |
| Jun 23, 2026 | Mario T Schlosser
Director
|
Grant | 1.0M | - |
| Jun 4, 2026 | William Gassen
Director
|
Grant | 8.5K | - |
| Jun 4, 2026 | Laura W Lang
Director
|
Grant | 8.5K | - |
| Jun 4, 2026 | David Plouffe
Director
|
Grant | 8.5K | - |
| Jun 4, 2026 | Siddhartha Sankaran
Director
|
Grant | 8.5K | - |
| Jun 4, 2026 | Vanessa Ames Wittman
Director
|
Grant | 8.5K | - |
| Jun 2, 2026 | Mario T Schlosser
Director
|
Sell | 34.1K | $748.6K |
| Jun 2, 2026 | Richard Scott Blackley
Chief Financial Officer
|
Sell | 31.7K | $695.2K |
| Jun 2, 2026 | Janet Liang
Officer
|
Sell | 12.5K | $273.7K |
| Jun 2, 2026 | Adam Mcananey
Officer
|
Sell | 9.9K | $216.3K |
| Jun 2, 2026 | Victoria Baltrus
Officer
|
Sell | 1.5K | $33.4K |
| May 18, 2026 | Richard Scott Blackley
Chief Financial Officer
|
Sell | 110.0K | $2.8M |
| May 14, 2026 | Richard Scott Blackley
Chief Financial Officer
|
Sell | 100.0K | $2.3M |
| Apr 6, 2026 | Mark T Bertolini
Chief Executive Officer
|
Buy | 1.0M | $11.9M |
| Apr 2, 2026 | Mark T Bertolini
Chief Executive Officer
|
Grant | 5.7M | - |
| Mar 12, 2026 | Richard Scott Blackley
Chief Financial Officer
|
Grant | 150.0K | - |
| Mar 2, 2026 | Mario T Schlosser
Chief Technology Officer
|
Sell | 24.3K | $325.8K |
| Mar 2, 2026 | Richard Scott Blackley
Chief Financial Officer
|
Sell | 19.2K | $257.4K |
| Mar 2, 2026 | Adam Mcananey
Officer
|
Sell | 18.7K | $250.5K |
| Mar 2, 2026 | Janet Liang
Officer
|
Sell | 7.5K | $99.8K |
| Mar 2, 2026 | Victoria Baltrus
Officer
|
Sell | 4.6K | $62.1K |
| Mar 2, 2026 | Victoria Baltrus
Officer
|
Grant | 17.3K | - |
| Mar 2, 2026 | Mark T Bertolini
Chief Executive Officer
|
Grant | 1.6M | - |
| Mar 2, 2026 | Richard Scott Blackley
Chief Financial Officer
|
Grant | 134.8K | - |
| Mar 2, 2026 | Janet Liang
Officer
|
Grant | 106.5K | - |
| Mar 2, 2026 | Adam Mcananey
Officer
|
Grant | 67.4K | - |
| Mar 2, 2026 | Mario T Schlosser
Chief Technology Officer
|
Grant | 189.1K | - |
| Jan 8, 2026 | Mario T Schlosser
Chief Technology Officer
|
Sell | 23.0K | $406.6K |
| Jan 8, 2026 | Mario T Schlosser
Chief Technology Officer
|
Grant | 23.0K | - |
| Jan 6, 2026 | Mario T Schlosser
Chief Technology Officer
|
Sell | 77.0K | $1.3M |
| Jan 6, 2026 | Mario T Schlosser
Chief Technology Officer
|
Grant | 77.0K | - |
| Jan 5, 2026 | Mario T Schlosser
Chief Technology Officer
|
Sell | 234.9K | $3.6M |
| Jan 5, 2026 | Mario T Schlosser
Chief Technology Officer
|
Grant | 146.7K | - |
| Dec 24, 2025 | Mario T Schlosser
Chief Technology Officer
|
Sell | 38.8K | $582.5K |
| Dec 2, 2025 | Richard Scott Blackley
Chief Financial Officer
|
Sell | 25.1K | $417.0K |
| Dec 2, 2025 | Mario T Schlosser
Chief Technology Officer
|
Sell | 24.0K | $397.6K |
| Dec 2, 2025 | Janet Liang
Officer
|
Sell | 7.3K | $121.7K |
| Dec 2, 2025 | Victoria Baltrus
Officer
|
Sell | 4.1K | $68.8K |
| Dec 2, 2025 | Adam Mcananey
Officer
|
Sell | 1.9K | $30.7K |
| Nov 12, 2025 | Mario T Schlosser
Chief Technology Officer
|
Sell | 391.5K | $6.0M |
| Nov 12, 2025 | Mario T Schlosser
Chief Technology Officer
|
Grant | 391.5K | - |
| Sep 22, 2025 | Mario T Schlosser
Chief Technology Officer
|
Sell | 395.0K | $7.3M |
| Sep 22, 2025 | Mario T Schlosser
Chief Technology Officer
|
Grant | 395.0K | - |
| Jun 4, 2025 | Jeffery H Boyd
Director
|
Grant | 14.1K | - |
| Jun 4, 2025 | William Gassen
Director
|
Grant | 14.1K | - |
| Jun 4, 2025 | Laura W Lang
Director
|
Grant | 14.1K | - |
| Jun 4, 2025 | David Plouffe
Director
|
Grant | 14.1K | - |
| Jun 4, 2025 | Siddhartha Sankaran
Director
|
Grant | 14.1K | - |
| Jun 4, 2025 | Vanessa Ames Wittman
Director
|
Grant | 14.1K | - |
| May 12, 2025 | Elbert O. Robinson Jr.
Director
|
Sell | 25.0K | $410.8K |
Source: TwelveData, from SEC Form 4 filings
OSCR stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.